<DOC>
	<DOCNO>NCT01760954</DOCNO>
	<brief_summary>A randomize study evaluate continue safety efficacy elagolix management moderate severe endometriosis-associated pain adult pre-menopausal female subject .</brief_summary>
	<brief_title>Study Evaluate Long-Term Safety Efficacy Elagolix Subjects With Moderate Severe Endometriosis-Associated Pain</brief_title>
	<detailed_description>This Phase 3 multicenter , double blind randomize study ass continue safety efficacy two dos elagolix ( Dose 1 Dose 2 ) premenopausal woman moderate severe endometriosis-associated pain complete 6 month treatment period pivotal study M12-665 ( NCT01620528 ) . Approximately 500 subject expect enroll approximately 200 site . The study consist 2 period : 1 . ) 6 month Treatment Period 2 . ) post treatment Follow-up period 12 month ( applicable ) . An electronic diary use collect endometriosis-associated pain , uterine bleeding , analgesic medication use endometriosis associate pain daily basis . Pregnancy test perform monthly throughout study . Subjects require use non-hormonal dual contraceptive study counsel appropriate effective form birth control promote pregnancy prevention .</detailed_description>
	<mesh_term>Endometriosis</mesh_term>
	<criteria>Completed 6 month Treatment Period pivotal study M12665 ( NCT01620528 ) Agrees use required birth control method study Month 6 Posttreatment Followup period Clinically significant gynecological condition Bone mineral density ( BMD ) loss great equal 8 percent spine , femoral neck total hip Plans become pregnant next 18 month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Gonadotropin-Releasing Hormone Antagonist</keyword>
	<keyword>Non-Menstrual Pelvic Pain ( NMPP )</keyword>
	<keyword>Dysmenorrhea ( DYS )</keyword>
	<keyword>Endometriosis associate pain</keyword>
	<keyword>Elagolix</keyword>
</DOC>